The following article features coverage from the American Urological Association (AUA) 2019 meeting. Click here to read more of Renal & Urology News’ conference coverage.

CHICAGO—Patients who have elevated platelet counts prior to surgery for high-risk nonmetastatic renal cell carcinoma (RCC) are at increased risk of cancer recurrence, new data presented at the 2019 American Urological Association annual meeting suggest.

Preoperative platelet counts above 250,000/μL of blood are independently associated with a significant 50% increased risk of recurrence compared with lower platelet counts, Emily L. Davidson, MD, of the University of Wisconsin in Madison, and colleagues reported.

“Integration of platelet count into risk stratification models may help identify patients who benefit from adjuvant therapy or clinical trial enrollment,” Dr Davidson’s team concluded in a study abstract.

She and her collaborators studied 1074 patients with pT3a or higher RCC who received treatment at 3 institutions during 2000 to 2016. Of these, 278 (25.9%) had RCC recurrence at a median of 9.9 months after surgery. The median overall follow-up for patients without recurrence was 19.3 months. The investigators had preoperative platelet counts for 98% of patients.

Read more of Renal & Urology News’ coverage of the AUA 2019 meeting by visiting the conference page.

Reference

Davidson EL, Master VA, Raman JD, et al. Platelet count is an independent predictor of post-surgical recurrence in high risk non-metastatic renal cell carcinoma. Presented at the 2019 American Urological Association annual meeting held May 3-6 in Chicago. Abstract PD46-06.